Prime Capital Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Prime Capital Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38M	Sell	8,694 -1,956	-18%	-$264K	0.01%	456
2026 Q1	$1.36M	Buy	10,650 +23	+0.2%	+$2.87K	0.02%	438
2025 Q4	$1.3M	Buy	10,627 +13	+0.1%	+$1.49K	0.02%	438
2025 Q3	$1.06M	Buy	10,614 +675	+7%	+$60.8K	0.01%	472
2025 Q2	$824K	Buy	9,939 +2,729	+38%	+$218K	0.01%	509
2025 Q1	$585K	Buy	7,210 +1,586	+28%	+$142K	0.01%	630
2024 Q4	$506K	Sell	5,624 -90	-2%	-$8.72K	0.01%	564
2024 Q3	$565K	Sell	5,714 -377	-6%	-$37K	0.01%	554
2024 Q2	$565K	Sell	6,091 -1,636	-21%	-$147K	0.01%	548
2024 Q1	$733K	Buy	7,727 +1,263	+20%	+$117K	0.01%	527
2023 Q4	$577K	Buy	6,464 +2,228	+53%	+$165K	0.01%	543
2023 Q3	$309K	Buy	4,236 +226	+6%	+$18.1K	0.01%	574
2023 Q2	$334K	Buy	+4,010	New	+$335K	0.01%	574
2023 Q1	–	Sell	-7,894	Closed	-$655K	–	670
2022 Q4	$655K	Buy	7,894 +5,194	+192%	+$421K	0.02%	293
2022 Q3	$214K	Buy	+2,700	New	+$228K	0.01%	368

Other funds holding XBI

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prime Capital Investment Advisors's XBI Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 18% in Q2 2026, selling an estimated $264K and leaving 8,694 shares worth $1.38M. The position accounts for 0.01% of the portfolio, ranked #456.

Prime Capital Investment Advisors first reported a position in XBI in Q3 2022 and has held it in 15 quarters since. 695 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Prime Capital Investment Advisors held 8,694 shares of State Street SPDR S&P Biotech ETF worth $1.38M as of Q2 2026.
Prime Capital Investment Advisors sold 1,956 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $264K.
State Street SPDR S&P Biotech ETF made up 0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #456 holding.
Prime Capital Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and has held it in 15 quarters since.
695 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.